Abstract: Genes encoding novel proteins named AID (Activation-Induced cytidine Deaminase), that are structurally related to APOBEC-1, an RNA editing enzyme, and have a cytidine deaminase activity similar to APOBEC-1, have been found by preparing cDNA libraries from mouse B cell clone CH12F3-2 (which undergoes class switch recombination from IgM to IgA at an extremely high rate after activation of the cells by stimulation with cytokines), with and without stimulation with cytokines, and performing subtraction cloning using the libraries.

Abstract: The invention provides polynucleotides and polypeptides encoding an isolated amyloid inhibitor protein (APIP) and compositions thereof. The polypeptides of the subject invention can be used to inhibit the catabolism or sequential cleavage of arnyloid beta precursor protein (APP) by Sequential cleavage of APP by beta secretase and gamma secretase.

Abstract: Isolated Dendritic Cell Transmembrane Serine Proteases (DCTSPs), DNAs encoding such DCTSPs, and pharmaceutical and/or diagnostic compositions made therefrom, are disclosed. The isolated DCTSPs can be used to hydrolyze peptide bonds. The DCTSPs are also useful in screening for inhibitors or agonists thereof.

Abstract: Novel human polynucleotide and polypeptide sequences are disclosed that can be used in therapeutic, diagnostic, and pharmacogenomic applications.

Abstract: This invention provides prokaryotic glycosyltransferases, including a bifunctional sialyltransferase that has both an &agr;2,3- and an &agr;2,8-activity. A &bgr;1,4-GalNAc transferase and a &bgr;1,3-galactosyltransferase are also provided by the invention, as are other glycosyltransferases and enzymes involved in synthesis of lipooligosaccharide (LOS). The glycosyltransferases can be obtained from, for example, Campylobacter species, including C. jejuni. In additional embodiments, the invention provides nucleic acids that encode the glycosyltransferases, as well as expression vectors and host cells for expressing the glycosyltransferases.

Abstract: The present invention relates to novel antithrombotic variants of thrombin or fragments thereof that are capable of proteolytically activating protein C, but which are substantially free of fibrinogen cleavage activity. The present invention further relates to variant polypeptidess that may be cleaved to yield active thrombin variants. The present invention also relates to methods of inhibiting thrombus formation in an animal or human subject by delivering an antithrombotic variant thrombin of the present invention to the blood of the subject. The present invention relates also to methods that use the novel variant thrombins for determining the level of protein C activation in a blood sample, or the thrombogenic potential of a patient.

Abstract: A mutated expandase enzyme having higher activity on penicillin G is provided to produce phenylacetyl-7-aminodeacetoxycephalosporanic acid (7-ADCA), which mutated expandase enzyme has one or more amino acid substitutions selected from M73T, G79E, V275I, L277K, C281Y, G300V, N304K, I305L and I305M.

Abstract: This invention provides prokaryotic glycosyltransferases, including a bifunctional sialyltransferase that has both an &agr;2,3- and an &agr;2,8-activity. A &bgr;1,4-GalNAc transferase and a &bgr;1,3-galactosyltransferase are also provided by the invention, as are other glycosyltransferases and enzymes involved in synthesis of lipooligosaccharide (LOS). The glycosyltransferases can be obtained from, for example, Campylobacter species, including C. jejuni. In additional embodiments, the invention provides nucleic acids that encode the glycosyltransferases, as well as expression vectors and host cells for expressing the glycosyltransferases.

Abstract: Novel human polynucleotide and polypeptide sequences are disclosed that can be used in therapeutic, diagnostic, and pharmacogenomic applications.

Abstract: A high growth methanotrophic bacterial strain capable of growth on a C1 carbon substrate has been isolated and characterized. The strain has the unique ability to utilize both methane and methanol as a sole carbon source and has been demonstrated to possess a functional Embden-Meyerhof carbon flux pathway. The possession of this pathway conveys an energetic advantage to the strain, making it particularly suitable as a production platform for the production of biomass from a C1 carbon source.

Abstract: A method br the fermentative preparation of D-pantothenic acid and/or its salts or feedstuff additives containing these. Said method comprising fermentation of Escherichia coli microorganisms wherein at least one of the nucleotide sequence(s) coding for the gcvT, gcvH, and gcvP gene is overexpressed.

Abstract: A method for the fermentative preparation of D-pantothenic acid and/or its salts or feedstuff additives containing these. Said method comprising, fermentation of Escherichia coli microorganisms wherein the nucleotide sequence(s) coding the glyA gene is overexpressed.

Abstract: The present invention is directed to genetic material useful for the preparation of actinol, such as an isolated DNA including a nucleotide sequence coding for an enzyme having levodione reductase activity, a polypeptide encoded by such a DNA, recombinant organisms, and the like. These genetic materials may originate from Corynebacterium, Cellulomonas, Planococcus, Arthrobacter, and the like. The present invention also provides a process for the production of actinol.

Abstract: The invention provides isolated nucleic acids molecules, designated 53010 nucleic acid molecules, which encode novel carboxylesterase members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 53010 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 53010 gene has been introduced or disrupted. The invention still further provides isolated 53010 proteins, fusion proteins, antigenic peptides and anti-53010 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.

Abstract: The invention relates to LYC4, a novel member of the lysozyme gene family. The invention provides the cDNA sequence encoding the novel lysozyme, the polypeptide encoded by the sequence, as well as methods for producing said novel human lysozyme utilizing recombinant technology. The invention also provides the use of the novel human lysozyme.

Abstract: The present invention provides a process of producing highly purified proteases. The invention further provides the use of such purified proteases in treating cardiovascular disorders, including hypertension, stroke and thrombosis.

Abstract: D-pantothenic acid and/or a salt thereof or feedstuffs additives comprising these are prepared by fermentation of a microorganism of the Enterobacteriaceae family, in particular one which already produces D-pantothenic acid, wherein the nucleotide sequence(s) in the microorganism which code(s) for the poxB gene is (are) attenuated, in particular eliminated.

Abstract: Human polynucleotide and polypeptide sequences for novel protein kinases are disclosed that can be used in therapeutic, diagnostic, and pharmacogenomic applications.

Abstract: Disclosed are a human polynucleotide and the encoded adenylsuccinate synthethase which, can be used in therapeutic, diagnostic, and pharmacogenomic applications.

Abstract: The present invention relates to human diacylglycerol kinase proteins (hDAGK) and particularly to human diacylglycerol kinase &bgr; (hDAGK&bgr;) protein, and to related nucleotide sequences, expression vectors, cell lines, antibodies, screening methods, compounds, methods of production and methods of treatment, as well as other related aspects.